blepharoconjunctivitis


Also found in: Dictionary, Thesaurus, Encyclopedia.

blepharoconjunctivitis

 [blef″ah-ro-kon-junk″tĭ-vi´tis]
inflammation of the eyelids and conjunctiva.

bleph·a·ro·con·junc·ti·vi·tis

(blef'ă-rō-kon-jŭnk'ti-vī'tis),
Inflammation of the palpebral conjunctiva.

bleph·a·ro·con·junc·ti·vi·tis

(blef'ă-rō-kŏn-jŭngk'ti-vī'tis)
Inflammation of the palpebral conjunctiva.

blepharoconjunctivitis

Inflammation of the eyelids and of the associated conjunctiva.

blepharoconjunctivitis 

Inflammation of the conjunctiva and eyelids. See herpes simplex keratitis.

blepharoconjunctivitis

inflammation of the eyelids and conjunctiva.
References in periodicals archive ?
Twenty-two percent of patients on pimecrolimus cream for atopic blepharoconjunctivitis discontinued the topical calcineurin inhibitor because of insufficient efficacy, compared with 1.
Data Source: This was a retrospective, single-center chart review of 338 patients on long-term topical therapy for atopic blepharoconjunctivitis.
For management of mild or suspected cases of bacterial conjunctivitis or blepharoconjunctivitis, diamidine treatment is appropriate as an initial measure.
The next near-term product opportunity in InSite's pipeline is ISV-502 (AzaSite Plus[TM]), a topical combination antibiotic/corticosteroid product for the treatment of blepharoconjunctivitis (also known as lid margin disease), a condition that currently has no approved therapy.
1 percent of subjects treated with ISV-502 met the clinical criteria necessary to demonstrate a resolution of the inflammatory signs and symptoms of blepharoconjunctivitis.
Blepharoconjunctivitis can be a chronic condition that is difficult to treat.
InSite announced today that enrollment is ahead of schedule and is more than 85% complete for its first Phase 3 pivotal clinical trial of ISV-502 under development for the treatment of blepharoconjunctivitis.
Initiated pivotal Phase 3 clinical trials to evaluate AzaSite Plus for the treatment of blepharoconjunctivitis, a frequently chronic inflammation of the conjunctiva and eye lids caused by infections or allergic reactions - December 20, 2007
InSite Vision (AMEX:ISV) announced today that it has initiated pivotal Phase 3 clinical trials to evaluate AzaSite Plus[TM] for the treatment of blepharoconjunctivitis, a frequently-chronic inflammation of the conjunctiva and eye lids caused by infections or allergic reactions.
There are three treatment arms with the objective that AzaSite Plus will show superiority in treating blepharoconjunctivitis over AzaSite[R] (azithromycin ophthalmic solution) 1% - InSite's topical anti-infective drug on the market to treat bacterial conjunctivitis (pink eye) - and superiority over dexamethasone.
There were 32 patients with blepharoconjunctivitis who completed the double-masked and randomized trial and received eye drops two times a day for 14 days.